Needham & Company Reiterate Buy on Seattle Genetics (SGEN) Following Adcetris Approval
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/16/2026
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Oil slips as Saudi Arabia offers more crude via Oman
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Exclusive-SK Hynix in talks with Intel about deal to make memory chips in US for the first time, sources say
- Trade the FOMC: How stocks tend to perform on Fed hike days
- Generac strikes $8B supply deal with Amazon for data center power
- U.S. Commerce Department to sell up to 9.9M GlobalFoundries shares
- AI chip sell-off overblown: Zero GPU slowdown after Anthropic essay, analyst says
- Wall Street ends lower as oil spikes and the benchmark Treasury yield breaches 5%
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
Seattle Genetics Announces FDA Regular Approval of ADCETRIS® (Brentuximab Vedotin) for Classical Hodgkin Lymphoma Patients at High Risk of Relapse or Progression as Post-Autologous Hematopoietic Stem
August 17, 2015 4:08 PM EDT-FDA Approval Based on the Phase 3 AETHERA Clinical Trial Results-
-AETHERA Trial Also Converts Prior Accelerated Approval to Regular Approval in Treatment of Classical Hodgkin Lymphoma Patients who Fail Autologous Hematopoietic Transplantation or who Fail at Least Two Prior Multi-Agent Chemotherapy Regimens and are Not Autologous Hematopoietic Transplantation Candidates-
-Label Expansion Represents Third Indication for ADCETRIS in the U.S. and the First of Four Phase 3 Clinical Trials Intended to Broaden the Global Use of ADCETRIS in CD30-Expressing Lymphomas-
-ADCETRIS is the Only FDA-Approved Therapy to Prolong Progression-Free Survival... More
